Related Experiment Videos
ACTH 1-17 effects in intrinsic bronchial asthma
La Ricerca in Clinica E in Laboratorio
|April 1, 1984
Summary
Adrenocorticotropic hormone (ACTH) 1-17 treatment normalized bronchial patency rhythms in asthma patients. This study found ACTH 1-17 improved lung function and was well-tolerated, with mild side effects.
Area of Science:
- Pulmonology
- Endocrinology
- Pharmacology
Background:
- Intrinsic asthma often presents with circadian patterns in bronchial patency.
- Nocturnal asthma exacerbations significantly impact patient quality of life.
- Understanding the chronobiology of asthma is crucial for effective treatment.
Purpose of the Study:
- To investigate the therapeutic effects of Synchrodyn 1-17 (ACTH 1-17) on intrinsic asthma.
- To assess the impact of ACTH 1-17 on bronchial patency and its circadian variations.
- To evaluate the safety and tolerability of ACTH 1-17 in asthma patients.
Main Methods:
- A study involving 12 patients with intrinsic asthma.
- Intramuscular administration of Synchrodyn 1-17 (100 micrograms/day) for 15 days.
- Monitoring of functional parameters related to bronchial patency and bronchial tone rhythms.
Main Results:
- Pathological circadian rhythms in bronchial tone were eliminated.
- Significant general improvement observed in bronchial patency indices.
- ACTH 1-17 demonstrated good tolerability in the study population.
Conclusions:
- Synchrodyn 1-17 (ACTH 1-17) effectively normalized bronchial tone rhythms in asthma.
- The treatment led to a marked improvement in lung function parameters.
- Mild side effects like euphoria and water retention were transient and reversible.